An Improved Method for the Determination of Reserpine in Plasma Using Liquid Chromatography with Fluorescence Detection

Quantitative liquid chromatographic-tandem mass spectrometric determination of reserpine in FVB/N mouse plasma using a "chelating" agent (disodium EDTA) for releasing protein-bound analytes during 96-well liquid-liquid extraction

A sensitive, specific, accurate and reproducible analytical method employing a divalent cation chelating agent (disodium EDTA) for sample treatment was developed to quantitate reserpine in FVB/N mouse plasma. Samples pretreated with 40 microl of 2% disodium EDTA in water were extracted by a semi-automated 96-well liquid-liquid extraction (LLE) procedure to isolate reserpine and a structural analog internal standard (I.S.), rescinnamine, from mouse plasma. The extracts were analyzed by turbo ionspray liquid chromatography-tandem mass spectrometry (LC-MS-MS) in the positive ion mode. Sample preparation time for conventional LLE was dramatically reduced by the semi-automated 96-well LLE approach. The assay demonstrated a lower limit of quantitation of 0.02 ng/ml using 0.1-ml plasma sample aliquots. The calibration curves were linear from 0.02 to 10 ng/ml for reserpine. The intra- and inter-assay precision of quality control (QC) samples ranged from 1.75 to 10.9% for reserpine. The intra- and inter-assay accuracy of QC samples ranged from -8.17 to 8.61%. Reserpine and the I.S. were found to be highly bound to FVB/N mouse plasma protein. This is the first report of disodium EDTA employed as a special protein-bound release agent to recover protein-bound analytes from plasma. These matrix effects and the effects of pH in the HPLC mobile phase on the sensitivities of LC-MS-MS are discussed in this paper.

Serotonin depletion induced by reserpine is attenuated by prophylactic administration of lithium

Prophylactic administration of lithium significantly attenuated the serotonin depleting effects of reserpine. In rat brain, lithium did not change the capacity of the storage protein, serotonin binding protein to bind the amine either in vivo or in vitro nor did it change its sensitivity to reserpine. However, the chronic administration of lithium significantly decreased reserpine levels in plasma and brain tissue of treated rats compared with rats which were treated only with reserpine. It is concluded that the antagonism between reserpine and lithium does not involve the serotonin binding protein but may be due to the lithium-induced reduction of reserpine levels.